296 related articles for article (PubMed ID: 17356271)
21. [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Akasaka O; Iwase S; Miwa H; Ando T; Morita S; Koh R; Kasama M; Matsueda R; Anan H
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1833-7. PubMed ID: 19920384
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T
J Cancer Res Clin Oncol; 2006 Dec; 132(12):781-5. PubMed ID: 16804723
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Baba E; Esaki T; Ariyama H; Mitsugi K; Morikita T; Fujishima H; Kusaba H; Nakano S; Akashi K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):611-7. PubMed ID: 21116623
[TBL] [Abstract][Full Text] [Related]
24. [Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].
Sunaga T; Suzuki S; Harada N; Tanaka S; Hayashi T; Suzuki M
Gan To Kagaku Ryoho; 2009 Apr; 36(4):589-93. PubMed ID: 19381029
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
Kemmochi T; Egawa T; Mihara Y; Irino T; Ito Y; Nagashima A; Makino H; Yamamuro W
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2351-3. PubMed ID: 22202379
[TBL] [Abstract][Full Text] [Related]
26. [Controversial issues in chemotherapy for inoperable gastric cancer].
Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama N; Nagaba S; Kitamura T; Azuma M; Saigenji K
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1249-55. PubMed ID: 14518402
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
Takahashi T; Saikawa Y; Fukuda K; Funakoshi S; Kawakubo H; Takeuchi H; Takaishi H; Kitagawa Y
Anticancer Res; 2012 Dec; 32(12):5401-6. PubMed ID: 23225443
[TBL] [Abstract][Full Text] [Related]
28. [A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1].
Watanabe T; Uchida M; Harada K; Homma N; Ogata N; Funada R; Hasegawa K; Soga K; Shibasaki K
Gan To Kagaku Ryoho; 2007 Apr; 34(4):605-8. PubMed ID: 17431349
[TBL] [Abstract][Full Text] [Related]
29. Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.
Chen L; Chen Q; Zhuang Z; Zhang Y; Tao J; Shen L; Shen X; Chen Z; Wang J; Zhu M; Wang H
Jpn J Clin Oncol; 2014 Mar; 44(3):208-13. PubMed ID: 24453274
[TBL] [Abstract][Full Text] [Related]
30. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139
[TBL] [Abstract][Full Text] [Related]
31. Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: a case report.
Takahashi N; Suzuki H; Iwabuchi S; Yamazaki Y; Yanaga K
Hepatogastroenterology; 2005; 52(61):326-8. PubMed ID: 15783061
[TBL] [Abstract][Full Text] [Related]
32. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
[TBL] [Abstract][Full Text] [Related]
33. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan plus S-1 for liver metastases of gastric cancer.
Kochi M; Fujii M; Kanamori N; Kaiga T; Okubo R; Hagiwara K; Funada T; Tamegai H; Takayama T
Hepatogastroenterology; 2009; 56(96):1755-9. PubMed ID: 20214232
[TBL] [Abstract][Full Text] [Related]
35. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
[TBL] [Abstract][Full Text] [Related]
36. [A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Aiko S; Yoshizumi Y; Sugiura Y; Ishizuka T; Sakano T; Kumano I; Maehara T
Gan To Kagaku Ryoho; 2006 Feb; 33(2):239-42. PubMed ID: 16484864
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Goto A; Sukawa Y; Igarashi H; Onodera K; Aoki Y; Suzuki K; Yonezawa K; Yawata A; Kobayashi T; Kaneto H; Shimizu H; Wakasugi H; Matsunaga Y; Itoh M; Okuda H; Arimura Y; Shinomura Y
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1461-6. PubMed ID: 21945893
[TBL] [Abstract][Full Text] [Related]
38. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
39. [Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Gotoh M; Kawabe S; Takiuchi H; Ohta S; Katsu K
Gan To Kagaku Ryoho; 2002 Dec; 29 Suppl 3():470-4. PubMed ID: 12536832
[TBL] [Abstract][Full Text] [Related]
40. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]